Analysts/Institutional Investor Meet/Con. Call Updates

July 09, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Dear Sir / Madam, Sub: Q1 FY27 Earnings Conference Call Invite Please find enclosed the Q1 FY27 Earnings conference call invite for the call scheduled on July 24, 2026 at 05.00 PM (IST). This is for your information and records. Thanking you, Yours faithfully, For Laurus Labs Limited G. Venkateswar Reddy Company Secretary & Compliance Officer Encl: A/a Laur us Labs Q1 FY27 Results Conference Call 24 July 2026 at 5:00pm IST Hyderabad, July 09, 2026: Laurus Labs Ltd (BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028), a leading research and development driven pharmaceutical and biotech company will organize a conference call to discuss Q1 FY27 results followed by an interactive Q&A. The call will be hosted by DAM Capital Advisors. Dial In and other details given below Date and Time Friday, July 24, 2026 - 5:00 pm IST Conference dial-in Primary Number +91 22 6280 1384 Secondary Number +91 22 7115 8285 Available all over India Singapore +8001012045 Hong Kong +800964448 USA +18667462133 UK +08081011573 Diamond Pass Event Link ***END*** Investors Relations Media Relations Vivek Kumar Karthik C T +91 40 3980 4366 T +91 40 3980 4380 investorrelations@lauruslabs.com mediarelations@lauruslabs.com Corporate Office Plot No. 103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India T +91 40 6659 4333, 2342 0500/501 F +91 40 6659 4320 Registered Office Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District – 531021, Andra Pradesh, India CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E info@lauruslabs.com, W lauruslabs.com About Laurus Labs As a research-driven pharmaceutical manufacturing organization, Laurus Labs has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients. Since our inception in 2005, we have been developing and manufacturing APIs and Intermediates. We have global leadership position in APIs, including Anti-retroviral, Oncology, Cardiovascular, and Gastro therapeutics. Our position was strengthened by our backward-integration and strong regulatory compliance across all operations. We emerged as one of the most trusted CMO and Contract Development and Manufacturing Organization (CDMO) service provider to Global Innovators from drug development phase to commercial manufacturing. Laurus employs over 8,126 people, including 3,134+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. During FY2026 Laurus generated ₹ 6,813 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated “BBB” by leading MSCI ESG Ratings. Corporate Identification No: L24239AP2005PLC047518. For more information visit www.lauruslabs.com Follow @ Laurus Labs on LinkedIn | Twitter | Facebook | Instagram